Vera Therapeutics Recruits Commercial Expert to Boost Investment Narrative

Vera Therapeutics has appointed James R. Meyers to its Board of Directors, bringing commercial expertise from Gilead and AstraZeneca. Meyers' experience in leading global launches adds weight to Vera's commercial ambitions. The appointment modestly strengthens the story around near-term catalysts but does not fundamentally change the binary clinical and regulatory risk. The core investment case remains on whether atacicept can transition from positive IgA nephropathy data into an approved, commercially meaningful product.